Acadia Healthcare Beats Q2 Revenue, Lifts 2026 Cash Flow Outlook by 23%
ACHC has more than doubled off its 52-week low of $11.43.
Summary
Acadia Healthcare posted Q2 revenue of $865.84M, beating the $844.23M consensus, and raised its full-year operating cash flow guidance to $350-$400M from $285-$325M — a 23% increase at the midpoint. Adjusted EBITDA of $149.20M edged past estimates despite a $39.3M jump in liability costs, including a $28.6M reserve adjustment. Acute inpatient volumes grew 5.5%, driven by 240 new beds, while revenue was held back by timing of supplemental payments in Florida and Tennessee. This follows a strong Q1 and a $105M jury award against a subsidiary in May, which may be contributing to the reserve build. The raised cash flow outlook signals confidence in underlying operations, though cost pressures bear watching.
At the time of this announcement, ACHC was trading at $30.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $11.43 to $35.83. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.